Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | RBP4 | P02753 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900625 | 0.86 | KDM4E (0.67) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1901227 | 0.85 | KDM4E (0.65) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL31705250 | 0.84 | MEN1 (0.50) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13894497 | 0.84 | MAPT (0.48) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1895339 | 0.82 | KDM4E (0.68) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1899907 | 0.80 | KDM4E (0.56) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2174789 | 0.80 | KDM4E (0.53) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12998521 | 0.79 | MAPT (1.00) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1897740 | 0.79 | CNR1 (0.56) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2173700 | 0.78 | KDM4E (0.56) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, ALDH1A2 | MAPT 864/4885KDM4E 4096/4885ALDH1A1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.